Literature DB >> 16613434

Disinhibition and borderline personality disorder.

Joel T Nigg1, Kenneth R Silk, Gillian Stavro, Torri Miller.   

Abstract

We review different conceptions of inhibitory control that may be relevant to the regulatory problems featured in borderline personality disorder (BPD). These conceptions have often been framed with regard to personality traits of inhibitory control, but can also be related to cognitive measures of response suppression as well as affect regulation. Reactive behavioral inhibition is relatively unstudied in relation to BPD. A substantial amount of literature links executive function problems with BPD, but that literature has not isolated executive response inhibition nor been controlled for other personality disorder symptoms of antisociality, attention-deficit/hyperactivity disorder (ADHD), or depression, anxiety, or posttraumatic symptoms. We therefore conducted a study of this question looking at BPD symptoms in an adult sample with a small number of BPD subjects and other disorders. Results indicated that symptoms of BPD were correlated with response inhibition (measured by stop signal reaction time) even after controlling for the overlap of stop inhibition with ADHD, antisociality, and other Axis II disorder symptoms. We conclude by hypothesizing discrete developmental routes to BPD, based on different mechanism breakdowns, which would be amenable to empirical investigation at the cognitive or trait level of analysis.

Entities:  

Mesh:

Year:  2005        PMID: 16613434     DOI: 10.1017/s0954579405050534

Source DB:  PubMed          Journal:  Dev Psychopathol        ISSN: 0954-5794


  31 in total

1.  Emotional conditions disrupt behavioral control among individuals with dysregulated personality traits.

Authors:  Jenessa Sprague; Edelyn Verona
Journal:  J Abnorm Psychol       Date:  2010-05

Review 2.  ESCAP Expert Article: borderline personality disorder in adolescence: an expert research review with implications for clinical practice.

Authors:  Peter Fonagy; Mario Speranza; Patrick Luyten; Michael Kaess; Christel Hessels; Martin Bohus
Journal:  Eur Child Adolesc Psychiatry       Date:  2015-08-14       Impact factor: 4.785

3.  Inhibition of Action, Thought, and Emotion: A Selective Neurobiological Review.

Authors:  Daniel G Dillon; Diego A Pizzagalli
Journal:  Appl Prev Psychol       Date:  2007-12

4.  Rejection Sensitivity and Executive Control: Joint predictors of Borderline Personality features.

Authors:  Ozlem Ayduk; Vivian Zayas; Geraldine Downey; Amy Blum Cole; Yuichi Shoda; Walter Mischel
Journal:  J Res Pers       Date:  2008-02

5.  Trajectories of attention deficit hyperactivity disorder and oppositional defiant disorder symptoms as precursors of borderline personality disorder symptoms in adolescent girls.

Authors:  Stephanie D Stepp; Jeffrey D Burke; Alison E Hipwell; Rolf Loeber
Journal:  J Abnorm Child Psychol       Date:  2012-01

6.  Executive control signals in orbitofrontal cortex during response inhibition.

Authors:  Daniel W Bryden; Matthew R Roesch
Journal:  J Neurosci       Date:  2015-03-04       Impact factor: 6.167

Review 7.  Impulsivity and Cluster B Personality Disorders.

Authors:  Daniel Turner; Alexandra Sebastian; Oliver Tüscher
Journal:  Curr Psychiatry Rep       Date:  2017-03       Impact factor: 5.285

8.  Guanfacine enhances inhibitory control and attentional shifting in early abstinent cocaine-dependent individuals.

Authors:  Helen Fox; Mehmet Sofuoglu; Rajita Sinha
Journal:  J Psychopharmacol       Date:  2015-01-07       Impact factor: 4.153

9.  Using diffusion models to understand clinical disorders.

Authors:  Corey N White; Roger Ratcliff; Michael W Vasey; Gail McKoon
Journal:  J Math Psychol       Date:  2010-02-01       Impact factor: 2.223

Review 10.  Impulsivity in borderline personality disorder: a matter of disturbed impulse control or a facet of emotional dysregulation?

Authors:  Alexandra Sebastian; Gitta Jacob; Klaus Lieb; Oliver Tüscher
Journal:  Curr Psychiatry Rep       Date:  2013-02       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.